Tyrosine-kinase inhibitors (TKI) in metastatic kidney cancer (mKC) treatment.

被引：0

作者：

Vladimirova, Liubov Yu ^{[1
]}

Kit, Oleg Ivanovich ^{[1
]}

Popova, Irina L. ^{[1
]}

Abramova, Natalya A. ^{[1
]}

机构：

[1] Rostov Sci Res Inst Oncol, Rostov Na Donu, Russia

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期

关键词：

D O I：

10.1200/jco.2014.32.15_suppl.e15546

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e15546

引用

页数：1

共 50 条

[21] USE OF TYROSINE KINASE INHIBITORS (TKI) IN HAEMODIALYTIC METASTATIC RENAL CELL CARCINOMA PATIENTS
Sabbatini, R.
Porta, C.
Procopio, G.
Ferrari, A.
Conte, P. F.
EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (04) : 185 - 185
[22] A new generation of EGFR tyrosine-kinase inhibitors in NSCLC
Hirsch, Fred R.
Bunn, Paul A., Jr.
LANCET ONCOLOGY, 2012, 13 (05): : 442 - 443
[23] Prolongation of the Secondary QT Interval with Tyrosine-Kinase Inhibitors
Debourdeau, P.
Stancu, A.
Debourdeau, V.
Serin, D.
ONCOLOGIE, 2016, 18 (01) : 47 - 54
[24] Tyrosine-kinase inhibitors in very rare sarcoma subtypes
Blay, J.
EJC SUPPLEMENTS, 2009, 7 (02): : 67 - 67
[25] Treatment by second-generation tyrosine-kinase inhibitors in patients with imatinib failure
Etienne, G.
ONCOLOGIE, 2012, 14 (10-11) : 589 - 595
[26] Cardiac monitoring in patients receiving tyrosine-kinase inhibitors
Kennes, Soetkin
Geraedts, Joost
ACTA CLINICA BELGICA, 2016, 71 : 35 - 35
[27] Drug-drug interactions with tyrosine-kinase inhibitors
Croes, Sander
de Vries, Frank
LANCET ONCOLOGY, 2014, 15 (10): : E416 - E416
[28] Tyrosine-kinase inhibitors—new standard for NSCLC therapy
Nagahiro Saijo
Nature Reviews Clinical Oncology, 2010, 7 : 618 - 619
[29] Who should receive EGFR tyrosine-kinase inhibitors?
Yu, Helena A.
Riely, Gregory J.
LANCET ONCOLOGY, 2012, 13 (11): : 1074 - 1076
[30] Tyrosine-kinase inhibitor sorafenib (S) in treatment of metastatic renal cell carcinoma cancer (mRCC) with lung metastases
Popova, Irina L.
Vladimirova, Liubov Yu
Abramova, Natalya A.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)

← 1 2 3 4 5 →